Investment Rating - The report suggests a "Watch" recommendation for the company [2][4]. Core Insights - Longyuan Co., Ltd. is recognized as a "small giant" in the automotive aluminum die-casting sector, with its performance driven by components for the three electric systems of new energy vehicles [2][3]. - The company specializes in the research, production, and sales of aluminum alloy precision die-casting parts, forming a core product system centered on automotive aluminum alloy precision die-casting parts [2][3]. - The company has established a stable customer structure with global automotive parts suppliers and vehicle manufacturers, including long-term partnerships with major clients like BorgWarner and Tesla [2][3][27]. Summary by Sections 1. Issuance Information - The issuance price is set at 24.7 CNY per share, with an issuance P/E ratio of 13.07X. The subscription date is March 23, 2026. The total number of shares issued is 17 million, accounting for 25% of the total share capital post-issuance [3][6][7]. 2. Company Overview - Longyuan Co., Ltd. focuses on aluminum alloy precision die-casting parts, with a projected gross margin of 23% for automotive parts in 2024 [15][22]. - The company has received numerous accolades, including being recognized as a national high-tech enterprise and a green factory [13][14]. - The company’s products are widely used in critical areas such as automotive engine systems and new energy vehicle three electric systems [17][19]. 3. Industry Insights - The demand for aluminum die-casting parts aligns with the automotive lightweight trend, with the per-vehicle aluminum usage in China expected to increase [3][22]. - The production and sales of new energy vehicles in China are projected to grow significantly, with a compound annual growth rate of approximately 53.76% from 2021 to 2024 [3][22]. - The global aluminum die-casting market is expected to grow from 80.2 billion USD in 2024 to 111.9 billion USD by 2030, with a CAGR of 5.71% [3][22]. 4. Subscription Recommendation - The report recommends paying attention to the company as it integrates into the new energy vehicle industry transformation, enhancing its core competitiveness through product strategy adjustments and increased R&D efforts [2][4].

Group 1: Fixed Income and Banking - The 2026 bond market is expected to perform better than anticipated, with a projected net issuance of around 20 trillion yuan, maintaining the same level as the previous year, and an increase in bank proprietary bond investments expected to reach 16 trillion yuan [2][8] - The anticipated policy interest rate cut of 10-20 basis points in 2026 is expected to lead to a corresponding decline in the Loan Prime Rate (LPR), with the 10Y government bond yield projected to fluctuate between 1.6% and 1.9% [2][8] - The credit investment strategy for March 2026 suggests a preference for medium-term duration strategies, with the M2 bank perpetual bonds showing significant outperformance compared to other bonds [9][10] Group 2: Media Industry - MiLian Technology has shown rapid revenue growth, with revenues increasing from 10.52 million yuan in 2022 to 19.17 million yuan in the first half of 2025, and a significant increase in average monthly active users by 45.81% year-on-year [14][15] - The company has expanded its application matrix, launching overseas market applications in 2024, which contributes to its growth potential in the online emotional market [14][15] - The platform fosters a vibrant user community through various interactive modes led by host users, enhancing user engagement and retention [15][16] Group 3: Pharmaceutical Industry - Yuan Dong Bio's revenue has grown from 162 million yuan in 2013 to 1.35 billion yuan in 2024, with a compound annual growth rate of 21.3%, driven by its anesthetic products and the strategic acquisition of Super Yang Pharmaceutical [18][19] - The company is focusing on innovative drug development, particularly in the CRBN molecular glue space, with its core product HP-001 showing Best-in-Class potential [18][19] - The internationalization of its anesthetic products is expected to contribute to revenue growth, with overseas sales increasing from 0.02 million yuan in 2017 to 0.25 million yuan in 2024 [20][21]

Economic Review and 2026 Outlook - In 2025, the actual GDP growth rates for Q1 to Q4 were 5.4%, 5.2%, 4.8%, and 4.5%, while nominal GDP growth rates were 4.6%, 3.9%, 3.7%, and 3.9% respectively, indicating a downward trend in actual GDP growth throughout the year [4][10] - Fixed asset investment (excluding rural households) decreased by 3.8%, the lowest since 2010, while retail sales of consumer goods grew by 3.7%, and export growth (in RMB terms) was 6.1% [4][19] - The economic state in 2025 was characterized by strong supply but weak demand, with resilient production and exports, but persistent weakness in domestic demand [4][19] 2026 Policy and Institutional Behavior Outlook - A moderately loose monetary policy is expected, with a forecasted policy interest rate cut of 10-20 basis points, and a potential reserve requirement ratio (RRR) cut of 50-100 basis points [4][62][66] - The net financing scale of government bonds in 2026 is projected to be around 13.8 trillion yuan, remaining stable compared to the previous year [4][76] - The influence of trading desks on the bond market is anticipated to weaken, while the pricing power of banks and insurance funds is expected to increase due to lower funding costs [4][62][79] Investment Recommendations - The bond market in 2026 is expected to perform better than anticipated, with a projected net issuance of around 20 trillion yuan and significant demand from banks and insurance funds [4][58] - The 10-year government bond yield is expected to fluctuate between 1.6% and 1.9%, while the 30-year government bond yield is projected to be between 1.9% and 2.4% [4][58] - Investors are advised to focus on opportunities in long-term bonds and to monitor oil price fluctuations and changes in risk appetite [4][58]

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - The report highlights the rapid revenue growth and significant improvement in profitability for the company, with revenues projected to reach RMB 23.73 billion in 2024 and RMB 19.17 billion in the first half of 2025, alongside a net profit margin increasing to 15.50% [4] - The company employs a multi-interaction model centered around host-led activities, fostering a vibrant user community with over 180,000 host users as of June 30, 2025 [4] - The report emphasizes the company's strong investment in technology and innovation, with R&D expenditures amounting to RMB 136.5 million in 2024, representing 5.8% of total revenue [4] - The online social market, particularly in China, is experiencing rapid growth, with the market expected to reach RMB 632 billion by 2024, capturing 29.5% of the global market [32] - The company is positioned as a market leader in the online emotional social sector, with a market share of 11.6% as of June 30, 2025 [42] Summary by Sections Company Overview - The company focuses on online emotional social networking, with a diverse product matrix leading to rapid revenue growth [5] - The company has expanded its product offerings since its inception in 2015, launching several applications including "Yidui" and "Tietie," with monthly active users exceeding 10 million by 2025 [7] Industry Overview - The global online social market is projected to grow from RMB 983 billion in 2020 to RMB 2,141 billion by 2024, with a CAGR of 21.5% [32] - The Chinese online emotional social market is expected to grow from RMB 246 billion in 2020 to RMB 632 billion by 2024, with a CAGR of 26.6% [32] Company Business - The company utilizes a host-led interaction model to enhance user engagement, with various interactive modes encouraging long-term platform use [4] - The product matrix includes applications targeting diverse demographics, such as "Yidui" for users around 30 years old and "Tietie" for younger users aged 18-30 [46] Financial Analysis - Revenue growth is robust, with projected revenues of RMB 23.73 billion in 2024 and a gross profit margin of 49.50% in the first half of 2025 [14] - R&D spending has been significant, with RMB 136.5 million allocated in 2024, reflecting the company's commitment to innovation [22] Future Development Strategy - The company plans to expand its user base and enhance user experience by developing new products and entering new overseas markets [68] - There is a focus on integrating AI technology to optimize user matching and enhance operational efficiency [68]

Investment Rating - The report maintains a "Buy" rating for the company, highlighting the stability of its main business and the uniqueness of its molecular glue platform [5][7]. Core Insights - The company has shown a robust revenue growth from CNY 162 million in 2013 to CNY 1.35 billion in 2024, with a compound annual growth rate (CAGR) of 21.3%. The market share of its anesthetic analgesic products continues to rise [6][9]. - The company is advancing from a model of "high-end generics + modified drugs" to "innovative anesthesia + molecular glue + small molecule innovative drugs," which is expected to significantly enhance its long-term growth trajectory [6][9]. - The core product HP-001, a CRBN molecular glue, demonstrates best-in-class potential and is positioned to capture a significant market share in the treatment of relapsed/refractory multiple myeloma and non-Hodgkin lymphoma [6][9]. Financial Performance and Forecast - The company forecasts revenues of CNY 1,332 million in 2025, with a year-on-year growth rate of -1.33%, followed by CNY 1,513 million in 2026 and CNY 1,728 million in 2027, with growth rates of 13.63% and 14.16% respectively [5][7]. - The projected net profit attributable to shareholders is CNY 283 million in 2025, CNY 313 million in 2026, and CNY 358 million in 2027, with corresponding growth rates of 18.79%, 10.63%, and 14.51% [5][7]. - The price-to-earnings (P/E) ratios are expected to be 38.69, 34.97, and 30.54 for the years 2025, 2026, and 2027 respectively [5][7]. Business Strategy and Product Pipeline - The company has a diverse product matrix in anesthetic analgesics, with 18 marketed products and over 20 in clinical development. The internationalization of its products is expected to contribute to revenue growth [6][9]. - The company is focusing on innovative drug development through its subsidiary, Chaoyang Pharmaceutical, which specializes in molecular glue and other cutting-edge technologies [6][9]. - The company is also advancing several small molecule candidates and has a robust pipeline that includes EP-9001A, EP-0226, and EP-0210, which are in various stages of clinical trials [6][9]. Market Position and Competitive Landscape - The company is positioned well within the market, with a significant share in the anesthetic analgesic sector, and is actively expanding its international presence [6][9]. - The report compares the company with peers such as Haikang Pharmaceutical, Puluo Pharmaceutical, Enhua Pharmaceutical, and Aosaikang, indicating a favorable competitive landscape for the company's growth strategy [5][7].

Group 1: Economic Data Overview - In January-February 2026, the year-on-year growth of social retail sales was +2.8%, an increase of 1.9 percentage points compared to December 2025, but a decrease of 0.89 percentage points compared to the entire year of 2025 [6][7] - Fixed asset investment (FAI) in January-February 2026 showed a year-on-year increase of +1.8%, recovering from a decline of -3.8% in 2025, primarily driven by strong infrastructure investment [8][9] - The industrial added value for large-scale enterprises increased by +6.3% year-on-year in January-February 2026, marking a significant acceleration compared to December 2025 [10][11] Group 2: Banking Sector Insights - The banking sector is experiencing a new normal of "quality over quantity" in credit growth, with a projected loan growth rate of around 6.0% for 2026, influenced by fiscal policies and a focus on supported industries [14][15] - Profitability in the banking sector is stabilizing, with retail risks still present but manageable; large state-owned banks are expected to maintain dividend value due to low valuations [16][17] - Investment strategies should focus on two main lines: banks with strong wealth management capabilities and low valuation targets, as well as city and rural commercial banks with controllable risks and strong profit certainty [17] Group 3: Jiangsu Bank Analysis - Jiangsu Bank, a leading city commercial bank in the Yangtze River Delta, holds a significant market share in loans and deposits within Jiangsu province, with a loan balance accounting for 7.23% of the province's total [19][20] - The bank's corporate lending is supported by strong demand in manufacturing and infrastructure, while retail lending is steadily growing, particularly in consumer loans [20][21] - Jiangsu Bank's financial performance is robust, with a return on equity (ROE) significantly higher than the industry average, and a declining non-performing loan ratio of 0.84% [22][23] Group 4: HaiNeng Technology Overview - HaiNeng Technology reported a revenue of 362 million yuan in 2025, a year-on-year increase of 16.63%, with a net profit of 42.13 million yuan, reflecting a substantial growth in profitability [25][26] - The company is expanding its product lines in high-end scientific instruments, with significant growth in sample preparation and chromatography products, and is expected to continue this trend in 2026 [26][27] - HaiNeng Technology emphasizes shareholder returns, planning to distribute a cash dividend of 1.00 yuan per 10 shares, alongside a share buyback of 348,900 shares [30]

Group 1 - The banking operating environment is characterized by a shift to a "quality over quantity" approach in credit growth, with a slowdown in RMB loan growth to 6% as of February 2026, influenced by weak credit demand and a focus on state-supported industries [4][14] - Fiscal policy remains proactive, with a projected general deficit rate of approximately 8.0% in 2026, which is expected to maintain a strong leverage effect on credit demand similar to 2025 [31][32] - The profitability of banks is gradually stabilizing, with state-owned banks showing positive profit growth due to fiscal policies, while smaller banks face operational pressures [7][35] Group 2 - Retail credit risk remains under pressure, with an increase in non-performing loans, particularly among smaller banks, although there is optimism for state-owned banks' asset quality [7][26] - The investment strategy emphasizes two main lines: focusing on wealth management capabilities in joint-stock banks and identifying city and rural commercial banks with controllable risks and strong profit certainty [6][35] - The credit growth momentum is shifting from traditional industries to emerging sectors supported by government policies, with significant growth in loans to green and high-tech enterprises [19][20]

1. Report Industry Investment Rating - Not provided in the given content 2. Core Viewpoints of the Report - The economic data at the beginning of 2026 improved, but the overall situation remained weak. The year-on-year growth rate of social retail sales from January to February was +2.8%, up 1.9 percentage points from December 2025 but down 0.89 percentage points from the whole year of 2025. The cumulative year-on-year growth rate of fixed asset investment was +1.8%, up 5.6 percentage points from the whole year of 2025. The year-on-year decline of real estate development investment narrowed but remained in a large negative growth range, and real estate sales accelerated their decline, which might suppress post-cycle consumption such as furniture and home appliances. The year-on-year growth rate of industrial added value above designated size was +6.3%, 1.1 percentage points faster than that in December 2025. Under the interweaving of internal and external factors, market expectations were frequently disturbed, and residents' consumption willingness and enterprises' investment confidence still needed to be restored. The supply pressure of the bond market was better than expected, and there might be certain pressure on economic growth. The risk of long-term bonds was low, and the yield was expected to decline. It was recommended to pay attention to the investment opportunities of long-duration bonds [2]. 3. Summary According to Relevant Catalogs Social Retail Sales - The growth rate of social retail sales rebounded but remained under pressure. From January to February, the year-on-year growth rate of social retail sales was +2.8%, 1.9 percentage points faster than that in December 2025, which might be affected by the Spring Festival holiday. The cumulative growth rate from January to February decreased by 0.89 percentage points compared with the whole year of 2025. The retail sales of grain, oil, food, and clothing, shoes, hats, and textiles above the quota increased by 10.2% and 10.4% respectively. The retail sales of communication equipment and household appliances and audio-visual equipment above the quota increased by 17.8% and 3.3% respectively. In the future, due to the high year-on-year growth rate of social retail sales in the first half of 2025 and the decline in the support of consumption policies in 2026, the year-on-year growth rate of social retail sales in the first half of 2026 might be under pressure [2]. Fixed Asset Investment - Fixed asset investment turned from decline to growth, with infrastructure leading the recovery and real estate still under pressure. The pressure of fixed asset investment was alleviated stage by stage. The cumulative year-on-year growth rate ended four consecutive months of negative growth and turned from decline to growth from January to February. The year-on-year decline of real estate development investment narrowed but remained in a deep negative growth range. From January to February, the year-on-year growth rate of fixed asset investment was +1.8%, up 5.6 percentage points from the whole year of 2025, mainly driven by strong infrastructure investment (contributing about 3 percentage points) and accelerated growth of manufacturing investment (pulling 0.8 percentage points), while the drag effect of real estate investment weakened [2]. Real Estate - Real estate sales accelerated their decline, and the decline of private investment narrowed but remained under pressure. From January to February, the sales area of new commercial housing was 92.93 million square meters, a year-on-year decrease of 13.5%, and the sales volume was 818.6 billion yuan, a year-on-year decrease of 20.2%. The sales area and volume of residential housing decreased by 15.9% and 21.8% respectively, which might suppress post-cycle consumption such as furniture and home appliances. The "sales - investment" negative feedback mechanism of real estate might still continue. At the end of February, the unsold area of commercial housing was 799.98 million square meters, a year-on-year increase of 0.1%, indicating potential inventory pressure. From January to February, private fixed asset investment decreased by 2.6% year-on-year, 3.8 percentage points narrower than that in the whole year of 2025, ending the trend of expanding negative growth for six consecutive months but still not turning positive [2]. Industrial Added Value - The growth rate of industrial added value above designated size accelerated, and the leading role of new kinetic energy increased. From January to February, the year-on-year growth rate of industrial added value above designated size was +6.3%, reaching a recent high, 1.1 percentage points faster than that in December 2025. The industrial production accelerated significantly and continued to recover. Among the three major categories, the mining industry, manufacturing industry, and production and supply of electricity, heat, gas, and water increased by 6.1%, 6.6%, and 4.7% respectively year-on-year, 0.7, 0.9, and 3.9 percentage points higher than that in December 2025. The added value of high-tech manufacturing and equipment manufacturing above designated size increased by 13.1% and 9.3% respectively year-on-year, faster than the overall industrial added value above designated size. With the gradual improvement of demand and the continuous release of policy effects, the industrial economy was expected to maintain a stable growth trend [2][3]. Economic Growth - Economic growth might still face certain pressure. In January - February 2026, China's foreign trade achieved a "good start", but domestic demand remained under pressure. The support of consumption policies declined, the growth rate of social retail sales rebounded but was overall weak, real estate sales accelerated their decline, and private investment remained in the negative growth range, which might restrict economic recovery. The geopolitical conflict in the Middle East pushed up international oil prices, the market lowered the expectation of the Fed's interest rate cut, and overseas trade frictions disturbed, so the resilience of future foreign trade growth needed to be observed. In terms of prices, in February 2026, the year-on-year increase of CPI rose significantly to 1.3% (a three - year high), and the year-on-year decline of PPI narrowed to -0.9%, with five consecutive months of positive month-on-month growth. The war between the US and Iran might further narrow the decline [3]. Bond Investment - The adjustment of long-term bonds might be an opportunity, and it was recommended to seize the band operation opportunities. Recently, the RMB appreciated significantly, which was beneficial to the Chinese bond market. Currently, the long-term bond positions of trading desks were still small, and the year-on-year recovery of PPI was a general market expectation, so the risk of long-term bonds might be low. The deposit interest rate was low, and insurance premiums were expected to grow rapidly. In March, the allocation of ultra-long bonds by insurance funds might increase, and the yield of the active 30Y Treasury bond was expected to fall below 2.20%. It was expected that the low point of the 10Y Treasury bond yield in the first quarter might reach 1.75%, and the low point in the second quarter was expected to reach 1.70%. It was expected that the 10-year Treasury bond yield in 2026 would fluctuate in the range of 1.6% - 1.9%. Currently, it was recommended to pay attention to the opportunities of old 30Y Treasury bonds, 10Y China Development Bank bonds, and long-duration sinking capital bonds [3].

Group 1: Real Estate Industry - The core viewpoint indicates that the real estate market is showing signs of recovery, with a notable increase in transaction volumes for both new and second-hand homes in key cities [2][10] - New homes in 42 key cities totaled 189 million square meters this week, a 28.6% increase month-on-month, while second-hand homes in 21 key cities reached 220 million square meters, up 19.2% month-on-month [7][8] - The Ministry of Natural Resources and the National Forestry and Grassland Administration issued a notice linking new land use to the revitalization of existing land, prioritizing major projects and public welfare over commercial real estate development [8][10] Group 2: Construction Materials Industry - The construction materials sector is experiencing a divergence in recovery rates due to upstream raw material price pressures, with a potential bottoming out of the real estate market [13][14] - The report suggests that industries with a favorable market position may benefit from price increases, while those in a weaker position may face accelerated market exit due to rising costs [13] - Specific sectors to watch include coatings and waterproofing for potential profit growth, while the tile and glass industries may struggle [13] Group 3: Non-Banking Financial Sector - CITIC Securities is highlighted as a leading brokerage firm expected to benefit from policies promoting "aircraft carrier-level brokerages" and increased industry concentration [17][18] - The firm has consistently ranked first in revenue and net profit, maintaining a leading position in investment banking and wealth management [17] - The company is projected to see significant growth in its investment banking business due to policy support, with a forecasted net profit of 301 billion yuan in 2025, growing at a rate of 38.5% [18] Group 4: Pharmaceutical Industry - InnoCare Pharma is positioned as an innovative player in the ADC (antibody-drug conjugate) market, focusing on global expansion and partnerships with major pharmaceutical companies [19][21] - The company has developed multiple ADC technology platforms and is advancing its pipeline, with key products expected to enter commercialization soon [20][21] - Revenue forecasts indicate a decline in 2025, followed by modest growth in subsequent years, reflecting the company's strategic positioning in the ADC space [21]

Investment Rating - The report assigns a "Buy" rating for Jiangsu Bank, marking its first coverage [5]. Core Insights - Jiangsu Bank is a leading city commercial bank deeply rooted in the Yangtze River Delta, with a competitive edge in return on equity (ROE) [5]. - The bank has demonstrated strong fundamentals, leading several key metrics in the industry [5]. Summary by Sections Market Performance - Closing price as of March 17, 2026, is CNY 10.91, with a yearly high of CNY 12.64 and a low of CNY 9.08 [3]. - Total market capitalization is CNY 200.21 billion, with a circulating market value of CNY 200.21 billion [3]. Business Overview - Jiangsu Bank has a significant presence in Jiangsu, with a loan market share of 7.23% as of mid-2025, leading among city commercial banks [6]. - The bank's total assets reached CNY 4.9 trillion by Q3 2025, marking a year-on-year growth of 27.8% [16]. - The bank's retail loans stood at CNY 686.5 billion, accounting for 27.8% of total loans as of Q3 2025 [6]. Financial Performance - Jiangsu Bank's operating income for Q3 2025 was CNY 672 billion, reflecting a year-on-year growth of 7.8% [20]. - The net profit attributable to shareholders for Q3 2025 was CNY 306 billion, with an annual growth of 8.3% [20]. - The bank's net interest margin for 2024 was 1.86%, higher than the A-share listed bank average of 1.51% [6]. Asset Quality - The non-performing loan (NPL) ratio was 0.84% as of Q3 2025, significantly lower than the A-share listed bank average of 1.21% [9]. - The bank's provision coverage ratio was 323% as of Q3 2025, indicating strong asset quality management [9]. Growth Prospects - Jiangsu Bank's net profit is projected to grow to CNY 348 billion in 2025, with a year-on-year growth rate of 9.2% [8]. - The bank's return on equity (ROE) is expected to be 13.6% in 2024, surpassing the A-share listed bank average of 10.1% [8]. Competitive Position - Jiangsu Bank has a diversified business model, focusing on corporate, retail, and middle-income businesses, which drives its growth [55]. - The bank's corporate loans are primarily directed towards manufacturing and infrastructure, with a combined loan balance of CNY 1.19 trillion, accounting for 48.9% of total loans as of mid-2025 [6][58].